Novavax Stock News

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Teladoc's position in the growing telemedicine industry could help it turn things around. Novavax's only approved product is going nowhere and its pipeline has too little to offer.

Investing in biopharmaceutical stocks comes with more risks than some other types of stocks.

Novavax's coronavirus franchise isn't performing well. The company has no other product close to approval.

There's a simple reason why short-squeeze stocks to buy represent a powerful catalyst: they're intuitive and easier to engage. Buying something and hoping that it appreciates in value represents an or

Novavax and Ocugen were early contenders in the coronavirus vaccine race -- but didn't meet investors' expectations in that market. As a result, shares of both companies have plummeted.

Big GameStop (NYSE: GME ) and AMC Entertainment (NYSE: AMC ) may have lost investor focus, but these meme stocks keep interests high. Of the many indicators aiding to time the market, short interest r

Healthcare stocks, especially biotech companies, are very risky for investors. Their share price can be highly volatile and surge higher or plummet lower based on news regarding a clinical trial, trea

Throughout the history of financial markets, there is ample evidence of irrational investor behavior leading to euphoria. Be it the Tulip Mania of 1634 or the Housing Bubble and the subsequent financi

Novavax has reported both positive and negative news in recent days, sending the shares higher, then lower. The company settled a dispute with a key customer, but quarterly earnings missed analysts' e

In 2022, Novavax canceled a purchase agreement with Gavi, leading to a dispute over $700 million in advance payments. A settlement has been reached, and Novavax may only pay up to $475 million back to

Novavax's (NVAX) fourth-quarter earnings and revenues miss estimates. Stock tanks on moderate revenue guidance for 2024.

Novavax, Inc. (NASDAQ:NVAX) shares fell over 27% on Wednesday as the Covid-19 vaccine maker warned of slowing sales ahead after missing earnings expectations in the final quarter. Revenue for the thre

The headline numbers for Novavax (NVAX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estim

Novavax Inc (NASDAQ:NVAX) missed  top- and bottom-line estimates  for the fourth quarter.